We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Hematology-Oncology

Hematology-Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Unveiling the Role of snoRNA-Derived RNAs in Hematopoiesis and Acute Myeloid Leukemia Prognosis
Hematology-OncologyHematopoiesisacute myeloid leukemia

Unveiling the Role of snoRNA-Derived RNAs in Hematopoiesis and Acute Myeloid Leukemia Prognosis

By MedXY|Sep 9, 2026

This article explores the expression and functional impact of snoRNA-derived RNAs in healthy blood formation and acute myeloid leukemia, highlighting their potential as biomarkers and therapeutic targets.

Targeting Retinoic Acid-Driven CD16hiCD177+ Neutrophils in Steroid-Resistant GI-GVHD: A Novel Therapeutic Avenue
Gastroenterologyneutrophils

Targeting Retinoic Acid-Driven CD16hiCD177+ Neutrophils in Steroid-Resistant GI-GVHD: A Novel Therapeutic Avenue

By MedXY|Sep 9, 2026

Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant gastrointestinal graft-versus-host disease (GI-GVHD). Inhibition of the retinoic acid receptor restores steroid sensitivity and improves outcomes in murin

Impact of Germline and Somatic DNMT3A Variants on Pulmonary Arterial Hypertension: A New Frontier in Biomarkers and Therapeutics
Cardiologypulmonary arterial hypertensionCHIP genes

Impact of Germline and Somatic DNMT3A Variants on Pulmonary Arterial Hypertension: A New Frontier in Biomarkers and Therapeutics

By MedXY|Sep 8, 2026

Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti

Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer
General SurgeryExosomal microRNALiver Metastasis

Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer

By MedXY|Sep 7, 2026

A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.

Longitudinal Assessment of Testicular Function in Boys with Hematological Malignancies: Insights and Clinical Implications
Clinical Updateschemotherapy effectsendocrine sequelae

Longitudinal Assessment of Testicular Function in Boys with Hematological Malignancies: Insights and Clinical Implications

By MedXY|Sep 4, 2026

This review synthesizes evidence on testicular endocrine function in boys undergoing treatment for hematological malignancies, highlighting reversible dysfunctions, Sertoli cell maturation delay, and the need for long-term endocrine surveil

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Hematology-Oncologypediatric oncologyCAR T-cell therapy

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

By MedXY|Sep 6, 2026

A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.

Reevaluating the Role of Direct Antiglobulin Testing in Low-Risk Neonates with ABO or RhD Incompatibility
Clinical UpdatesABO incompatibilityneonatal hyperbilirubinemia

Reevaluating the Role of Direct Antiglobulin Testing in Low-Risk Neonates with ABO or RhD Incompatibility

By MedXY|Sep 4, 2026

Routine DAT offers limited additional clinical value over transcutaneous bilirubin monitoring in low-risk ABO and RhD-incompatible neonates, supporting guideline shifts towards selective DAT use and emphasizing maternal antibody screening.

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes
Hematology-Oncologypediatric AMLre-induction therapy

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes

By MedXY|Sep 3, 2026

This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management
Hematology-OncologyruxolitinibPhase II Trial

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management

By MedXY|Sep 3, 2026

The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.

Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial
Hematology-OncologysurvivalVCd

Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial

By MedXY|Sep 3, 2026

The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma
Clinical Updatesmultiple myelomaIKZF3

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma

By MedXY|Sep 3, 2026

Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.

Septic Shock in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: Outcomes, Prognostic Factors, and Clinical Implications from a Multicenter ICU Cohort
Critical Careseptic shockAllogeneic Hematopoietic Stem Cell Transplantation

Septic Shock in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: Outcomes, Prognostic Factors, and Clinical Implications from a Multicenter ICU Cohort

By MedXY|Sep 3, 2026

Septic shock following allogeneic hematopoietic stem-cell transplantation has a high 90-day mortality rate of 63%, strongly influenced by illness severity, fungal infection, and neutropenia. Early aminoglycoside use shows complex associatio

Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial Modulation
Hematology-Oncologytargeted therapyCheminformatics

Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial Modulation

By MedXY|Sep 1, 2026

Cheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlighting

Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies
Hematology-Oncologyaxi-celCD19-CAR-T therapy

Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies

By MedXY|Sep 1, 2026

Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms
Hematology-OncologyAneuploidyComplex Karyotype

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms

By MedXY|Sep 1, 2026

Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 Trial
Hematology-OncologyIbrutinibgenetic risk factors

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 Trial

By MedXY|Sep 1, 2026

The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke: New Insights from the SECRETO Study
Hematology-Oncologycryptogenic ischemic strokevenous thrombosis risk factors

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke: New Insights from the SECRETO Study

By MedXY|Aug 31, 2026

This multicenter study reveals that recent mechanical venous thrombosis risk factors markedly increase the risk of cryptogenic ischemic stroke in young adults, especially in those under 40 and with patent foramen ovale, independent of throm

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke
Hematology-Oncologycryptogenic ischemic strokemechanical risk factors

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke

By MedXY|Aug 29, 2026

This multicenter study reveals that recent mechanical venous thrombosis risk factors within 14 days significantly increase the risk of cryptogenic ischemic stroke in young adults, notably in those under 40 and with patent foramen ovale, ind

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients
Hematology-Oncologybiosimilarscancer biologics

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

By MedXY|Aug 29, 2026

This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients
CardiologyHematologic MalignanciesPIGR

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients

By MedXY|Aug 29, 2026

Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.

Prev
3 / 24
12345…24
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles